NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
![Cover of Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews](/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-dare-lrg.png)
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsCRD summary
The authors concluded that until good quality trials demonstrating its efficacy were available, Irvingia gabonensis (African bush mango) could not be recommended as a weight loss aid. The authors acknowledged the limitations of their review; their conclusion and recommendation for the need for further research seems appropriate.
Authors' objectives
To evaluate the effectiveness of Irvingia gabonensis supplementation in overweight and obese humans.
Searching
MEDLINE, EMBASE, AMED and The Cochrane Library were searched from inception up to April 2012. Search terms were reported. Conference proceedings, relevant medical journals and references of relevant article were searched, as well as the authors’ own files. No language restrictions were applied.
Study selection
Randomised controlled trials (RCTs) that compared orally administered Irvingia gabonensis with placebo for weight reduction in overweight (BMI 25 to 29.9kg/m2) or obese (BMI≥30kg/m2) participants were eligible. The included trials had to report body weight or body composition as an outcome measure. Trials were included irrespective of whether they incorporated lifestyle modifications.
All participants in the included trials were of African origin. The daily dosage of I. gabonensis varied between trials. Two RCTs had I. gabonensis as the sole intervention; the remaining RCT used I. gabonensis with another herbal supplement. Participants in two RCTs had a restricted daily calorie intake. The intervention period ranged from four to 10 weeks.
Two reviewers independently assessed the studies for eligibility.
Assessment of study quality
Two reviewers assessed trial quality using the Consolidated Standard of Reporting Trials Statement and the Preferred Reporting Items for Systematic Review and Meta-analyses guidelines. Items covered included randomisation, allocation concealment, blinding, baseline similarity, sample size calculation and attrition, and whether or not intention-to-treat analysis was used. Disagreements were resolved through discussion.
Data extraction
Data were extracted by two reviewers.
Methods of synthesis
The studies were combined in a narrative synthesis.
Results of the review
Three RCTs (two parallel and one cross-over) were included in the review (208 participants, range 72 to 120). None of the trials reported appropriate randomisation or allocation concealment. No RCTs reported outcome assessors as being blinded; two RCTs, patients and care provider were blinded. One RCT did not have similar characteristics at baseline. None of the RCTs performed an intention-to-treat analysis or reported sample size calculation or attrition.
All three trials reported a statistically significant reduction in body weight with Irvingia gabonensis compared with placebo (12.8kg versus 0.7kg; 4.1kg versus 0.1kg; 11.9kg versus 2.1kg). Significant weight loss continued up to a 10 week period (>5% from baseline). Two RCTs reported significant reductions of body fat with I. gabonensis compared with placebo (6.3% versus 2.0% and 20.1% versus 4.0%), but one RCT did not.
All RCTs reported statistically significant changes in waist circumferences with I. gabonensis (-16.2cm versus -53cm; -6.2cm versus +5.5cm; -21.9cm versus -1.0cm). One RCT reported significant reduction in hip circumference with I. gabonensis (-4.5cm versus -0.7cm) compared with placebo.
All RCTs suggested positive effects of I. gabonensis on the blood lipid profile.
Two RCTs reported adverse events including headache, sleep difficulties, and flatulence. There were no significant differences between Irvingia gabonensis and placebo for adverse events.
Authors' conclusions
Until good quality trials were available that demonstrate its efficacy, Irvingia gabonensis could not be recommended as a weight loss aid.
CRD commentary
The review question and inclusion criteria were clear. Efforts were made to find published and unpublished studies, which minimised the risk of publication bias. No language restrictions were applied, which reduced potential language bias. Attempts were made to minimise reviewer errors and bias in the review process.
Trial quality was assessed using appropriate criteria and the results were reported. A narrative synthesis was appropriate given the variation in trial methodology. The authors acknowledged the limitations of their review including small sample sizes, clinical heterogeneity, poor quality trials, generalisability, and possible publication bias.
The authors’ conclusion and recommendation for the need for further research seems appropriate.
Implications of the review for practice and research
Practice: The authors stated that while waiting for the further evidence, Irvingia gabonensis could not be recommended as a weight loss aid.
Research: The authors stated that larger rigorous studies were needed including volunteers from other racial background to enable a broader and more objective evaluation of the effects of I. gabonensis. Future studies should be longer in duration and included large post-marketing surveillance studies to determine safety.
Funding
One author was funded by a Glaxo SmithKline grant.
Bibliographic details
Onakpoya I, Davies L, Posadzki P, Ernst E. The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review of randomized controlled trials. Journal of Dietary Supplements 2013; 10(1): 29-38. [PubMed: 23419021]
Indexing Status
Subject indexing assigned by NLM
MeSH
Cellulose /adverse effects; Dietary Supplements; Headache /chemically induced; Humans; Lipids /blood; Obesity /drug therapy; Overweight; Phytotherapy; Plant Extracts /adverse effects /pharmacology /therapeutic use; Sleep Initiation and Maintenance Disorders /chemically induced; Waist Circumference /drug effects; Weight Loss /drug effects
AccessionNumber
Database entry date
12/08/2013
Record Status
This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results and conclusions followed by a detailed critical assessment on the reliability of the review and the conclusions drawn.
- CRD summary
- Authors' objectives
- Searching
- Study selection
- Assessment of study quality
- Data extraction
- Methods of synthesis
- Results of the review
- Authors' conclusions
- CRD commentary
- Implications of the review for practice and research
- Funding
- Bibliographic details
- Indexing Status
- MeSH
- AccessionNumber
- Database entry date
- Record Status
- The Effects of Irvingia gabonensis Seed Extract Supplementation on Anthropometric and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.[J Am Coll Nutr. 2020]The Effects of Irvingia gabonensis Seed Extract Supplementation on Anthropometric and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.Lee J, Chung M, Fu Z, Choi J, Lee HJ. J Am Coll Nutr. 2020 Jul; 39(5):388-396. Epub 2019 Dec 19.
- IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation.[Lipids Health Dis. 2009]IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation.Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. Lipids Health Dis. 2009 Mar 2; 8:7. Epub 2009 Mar 2.
- African mango (IGOB131): a proprietary seed extract of Irvingia gabonensis is found to be effective in reducing body weight and improving metabolic parameters in overweight humans.[Holist Nurs Pract. 2011]African mango (IGOB131): a proprietary seed extract of Irvingia gabonensis is found to be effective in reducing body weight and improving metabolic parameters in overweight humans.Ross SM. Holist Nurs Pract. 2011 Jul-Aug; 25(4):215-7.
- Review Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials.[Obes Rev. 2013]Review Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials.Onakpoya I, Posadzki P, Ernst E. Obes Rev. 2013 Jun; 14(6):496-507. Epub 2013 Mar 18.
- Review The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials.[J Am Coll Nutr. 2014]Review The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials.Onakpoya I, Posadzki P, Ernst E. J Am Coll Nutr. 2014; 33(1):70-8.
- The efficacy of Irvingia gabonensis supplementation in the management of overwei...The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review of randomized controlled trials - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
- DEXI Dexi homolog [Homo sapiens]DEXI Dexi homolog [Homo sapiens]Gene ID:28955Gene
- 28955[uid] AND (alive[prop]) (1)Gene
- Gm24698 predicted gene, 24698 [Mus musculus]Gm24698 predicted gene, 24698 [Mus musculus]Gene ID:115485642Gene
- LINC01965 long intergenic non-protein coding RNA 1965 [Homo sapiens]LINC01965 long intergenic non-protein coding RNA 1965 [Homo sapiens]Gene ID:107985928Gene
Your browsing activity is empty.
Activity recording is turned off.
See more...